Oculus Innovative Sciences, Inc. announced it has finalized a strategic collaborative agreement with the Lipogrid Company of Sweden to develop multiple topical drug delivery formulations based upon the company's Lipogrid® Technology.
Clinical testing has demonstrated that Lipogrid-based products deliver phospholipid building blocks to the dermis while protecting the skin.
The first Lipogrid-based prescription product received FDA 510(k) clearance in November 2015.
